The present invention is related to an endovascular delivery system for an endovascular prosthesis. More particularly, the present invention is related to an endovascular delivery system having a bifurcated and inflatable prosthesis having a tether from a contralateral leg to restrain movement of the contralateral leg with respect to an ipsilateral leg of the prosthesis.
An aneurysm is a medical condition indicated generally by an expansion and weakening of the wall of an artery of a patient. Aneurysms can develop at various sites within a patient's body. Thoracic aortic aneurysms (TAAs) or abdominal aortic aneurysms (AAAs) are manifested by an expansion and weakening of the aorta which is a serious and life threatening condition for which intervention is generally indicated. Existing methods of treating aneurysms include invasive surgical procedures with graft replacement of the affected vessel or body lumen or reinforcement of the vessel with a graft.
Surgical procedures to treat aortic aneurysms can have relatively high morbidity and mortality rates due to the risk factors inherent to surgical repair of this disease as well as long hospital stays and painful recoveries. This is especially true for surgical repair of TAAs, which is generally regarded as involving higher risk and more difficulty when compared to surgical repair of AAAs. An example of a surgical procedure involving repair of an AAA is described in a book titled Surgical Treatment of Aortic Aneurysms by Denton A. Cooley, M.D., published in 1986 by W.B. Saunders Company.
Due to the inherent risks and complexities of surgical repair of aortic aneurysms, endovascular repair has become a widely-used alternative therapy, most notably in treating AAAs. Early work in this field is exemplified by Lawrence, Jr. et al. in “Percutaneous Endovascular Graft Experimental Evaluation”, Radiology (May 1987) and by Mirich et al. in “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study,” Radiology (March 1989). Commercially available endoprostheses for the endovascular treatment of AAAs include the Endurant™ and Talent™ Abdominal Stent Grafts sold by Medtronic, Inc. of Minneapolis, Minn.; the Zenith Flex® AAA Endovascular Graft and the Zenith TX2® TAA Endovascular Graft, both sold by Cook Medical, Inc. of Bloomington, Ind.; the AFX™ Endovascular AAA system sold by Endologix, Inc. of Irvine, Calif.; and the Gore® Excluder® AAA Endoprosthesis sold by W.L. Gore & Associates, Inc. of Flagstaff, Ariz. A commercially available stent graft for the treatment of TAAs is the Gore® TAG® Thoracic Endoprosthesis sold by W.L. Gore & Associates, Inc. of Flagstaff, Ariz.
When deploying devices by catheter or other suitable instrument, it is advantageous to have a flexible and low profile stent graft and delivery system for passage through the various guiding catheters as well as the patient's sometimes tortuous anatomy. Many of the existing endovascular devices and methods for treatment of aneurysms, while representing significant advancement over previous devices and methods, use systems having relatively large transverse profiles, often up to 24 French. Also, such existing systems have greater than desired lateral stiffness, which can complicate the delivery process. In addition, the sizing of stent grafts may be important to achieve a favorable clinical result. In order to properly size a stent graft, the treating facility typically must maintain a large and expensive inventory of stent grafts in order to accommodate the varied sizes of patient vessels due to varied patient sizes and vessel morphologies. Alternatively, intervention may be delayed while awaiting custom size stent grafts to be manufactured and sent to the treating facility. As such, minimally invasive endovascular treatment of aneurysms is not available for many patients that would benefit from such a procedure and can be more difficult to carry out for those patients for whom the procedure is indicated. What have been needed are stent graft systems, delivery systems and methods that are adaptable to a wide range of patient anatomies and that can be safely and reliably deployed using a flexible low profile system.
In one aspect of the present invention an endovascular delivery system includes a bifurcated and inflatable prosthesis including a main tubular body having an open end and opposed ipsilateral and contralateral legs defining a graft wall therein between, the ipsilateral and contralateral legs having open ends, and the main tubular body and the ipsilateral and contralateral legs having inflatable channels; the ipsilateral leg including an ipsilateral tab extending from the open end of the ipsilateral leg, the tab including at least two holes; an elongate guidewire having at least two outwardly projecting members, the outwardly projecting members being sized to at least partially fit within the at least one of the at least two holes of the ipsilateral tab; a release wire slidable disposed within the at least two outwardly projecting members of the elongate guidewire and within one of the at least two holes of the ipsilateral tab; and a tether having opposed contralateral and ipsilateral ends, the contralateral end of the tether being securably disposed at the open end of the contralateral leg, the ipsilateral end of the tether having a hole, the release wire being slidably disposed through the hole of the tether to so engage the tether; wherein withdrawal of the release wire releases the ipsilateral tab and the tether from the elongate guidewire. The elongate guidewire may be extendable through the ipsilateral leg and through the main tubular body.
When the release wire engages the tether, the open end of the contralateral leg is proximally disposed and restrained towards the open end of the ipsilateral leg. In such a restrained position, the contralateral leg is restricted from significant longitudinal movement so as to prevent bunching up of the contralateral leg and is also is restricted from significant rotational movement so as to prevent misalignment within a bodily lumen.
The endovascular delivery system may further include an elongate outer tubular sheath having an open lumen and opposed proximal and distal ends with a medial portion therein between, the proximal end of the outer tubular sheath securably disposed to a first handle; an elongate inner tubular member having a tubular wall with an open lumen and opposed proximal and distal ends with a medial portion therein between, the inner tubular member having a longitudinal length greater than a longitudinal length of the outer tubular sheath, the inner tubular member being slidably disposed within the open lumen of the outer tubular sheath, the proximal end of the inner tubular member securably disposed to a second handle; the elongate guidewire slidably disposed within the inner tubular member; the distal end of the outer tubular sheath being slidably disposed past and beyond the distal end of the inner tubular member to define a prosthesis delivery state and slidably retractable to the medial portion of the inner tubular member to define a prosthesis unsheathed state.
The prosthesis may include non-textile polymeric material; for example, polytetrafluoroethylene. In some embodiments, the polytetrafluoroethylene may be non-porous polytetrafluoroethylene. The prosthesis may further include a metallic expandable member securably disposed at or near the open end of the main tubular body of the prosthesis.
In another aspect of the present invention, a method for delivering a bifurcated prosthesis, includes providing a bifurcated and inflatable prosthesis including: a main tubular body having an open end and opposed ipsilateral and contralateral legs defining a graft wall therein between, the ipsilateral and contralateral legs having open ends, and the main tubular body and the ipsilateral and contralateral legs having inflatable channels; the ipsilateral leg including an ipsilateral tab extending from the open end of the ipsilateral leg, the tab including at least two holes; providing an elongate guidewire having at least two outwardly projecting members, the outwardly projecting members being sized to at least partially fit within at least one of the at least two holes of the ipsilateral tab; providing a release wire slidable disposed within the at least two outwardly projecting members of the elongate guidewire and within the at least two holes of the ipsilateral tab; providing a tether having opposed contralateral and ipsilateral ends, the contralateral end of the tether being securably disposed at the open end of the contralateral leg, the ipsilateral end of the tether having a hole, the release wire being slidably disposed through the hole of the tether to so engage the tether; and withdrawing the release wire to release the ipsilateral tab and the tether from the elongate guidewire.
When the release wire engages the tether, the open end of the contralateral leg is proximally disposed and restrained towards the open end of the ipsilateral leg and the contralateral leg is restricted from significant longitudinal movement so as to prevent bunching up of the contralateral leg. The contralateral leg is also restricted from significant rotational movement so as to prevent misalignment within a bodily lumen.
In some aspects of the present invention, the endovascular prosthesis may be a modular endovascular graft assembly including a bifurcated main graft member formed from a supple graft material having a main fluid flow lumen therein. The main graft member may also include an ipsilateral leg with an ipsilateral fluid flow lumen in communication with the main fluid flow lumen, a contralateral leg with a contralateral fluid flow lumen in communication with the main fluid flow lumen and a network of inflatable channels disposed on the main graft member. The network of inflatable channels may be disposed anywhere on the main graft member including the ipsilateral and contralateral legs. The network of inflatable channels may be configured to accept a hardenable fill or inflation material to provide structural rigidity to the main graft member when the network of inflatable channels is in an inflated state. The network of inflatable channels may also include at least one inflatable cuff disposed on a proximal portion of the main graft member which is configured to seal against an inside surface of a patient's vessel. The fill material can also have transient or chronic radiopacity to facilitate the placement of the modular limbs into the main graft member. A proximal anchor member may be disposed at a proximal end of the main graft member and be secured to the main graft member. The proximal anchor member may have a self-expanding proximal stent portion secured to a self-expanding distal stent portion with struts having a cross sectional area that is substantially the same as or greater than a cross sectional area of proximal stent portions or distal stent portions adjacent the strut. At least one ipsilateral graft extension having a fluid flow lumen disposed therein may be deployed with the fluid flow lumen of the graft extension sealed to and in fluid communication with the fluid flow lumen of the ipsilateral leg of the main graft member. At least one contralateral graft extension having a fluid flow lumen disposed therein may be deployed with the fluid flow lumen of the graft extension sealed to and in fluid communication with the fluid flow lumen of the contralateral leg of the main graft member. For some embodiments, an outside surface of the graft extension may be sealed to an inside surface of the contralateral leg of the main graft when the graft extension is in a deployed state. For some embodiments, the axial length of the ipsilateral and contralateral legs may be sufficient to provide adequate surface area contact with outer surfaces of graft extensions to provide sufficient friction to hold the graft extensions in place. For some embodiments, the ipsilateral and contralateral legs may have an axial length of at least about 2 cm. For some embodiments, the ipsilateral and contralateral legs may have an axial length of about 2 cm to about 6 cm; more specifically, about 3 cm to about 5 cm.
In another aspect of the present invention, an endovascular prosthesis may include a bifurcated and inflatable prosthesis having a main tubular body having an open end and opposed ipsilateral and contralateral legs defining a graft wall therein between, where the ipsilateral and contralateral legs have open ends, and further where the main tubular body and the ipsilateral and contralateral legs have inflatable channels; and a web of biocompatible material disposed between the contralateral leg and the ipsilateral leg and secured to the contralateral leg and the ipsilateral leg. The inclusion of the web with the endovascular prosthesis may prevent, restrict or inhibit the contralateral leg from significant longitudinal movement so as to prevent bunching up of the contralateral leg during delivery of the endovascular prosthesis. The inclusion of the web with the endovascular prosthesis may also prevent, restrict or inhibit significant rotational movement of the contralateral leg during delivery so as to prevent misalignment within a bodily lumen. The web may be releasably secured to the contralateral leg and the ipsilateral leg.
These and other features and advantages of the present invention will become apparent from the following detailed description of illustrative embodiments thereof, which is to be read in connection with the accompanying drawings. Corresponding reference element numbers or characters indicate corresponding parts throughout the several views of the drawings.
Embodiments of the invention are directed generally to methods and devices for treatment of fluid flow vessels with the body of a patient. Treatment of blood vessels is specifically indicated for some embodiments, and, more specifically, treatment of aneurysms, such as abdominal aortic aneurysms. With regard to graft embodiments discussed herein and components thereof, the term “proximal” refers to a location towards a patient's heart and the term “distal” refers to a location away from the patient's heart. With regard to delivery system catheters and components thereof discussed herein, the term “distal” refers to a location that is disposed away from an operator who is using the catheter and the term “proximal” refers to a location towards the operator.
The endovascular delivery system 100 may be advanced into the aorta 10 of the patient until the endovascular prosthesis (not shown) is disposed substantially adjacent an aortic aneurysm 20 or other vascular defect to be treated. The portion of the endovascular delivery system 100 that is advance through bodily lumens is in some embodiments a low profile delivery system; for example, having an overall outer diameter of less than 14 French. Other diameters are also useful, such as but not limited to less than 12 French, less than 10 French, or any sizes from 10 to 14 French or greater. Once the endovascular delivery system 100 is so positioned, an outer sheath 104 of the endovascular delivery system 100 may be retracted distally so as to expose the prosthesis (not shown) which has been compressed and compacted to fit within the inner lumen of the outer sheath 104 of the endovascular delivery system 100.
As depicted in
In some embodiments, the endovascular prosthesis 106 includes an inflatable graft 114. The inflatable graft may be a bifurcated graft having a main graft body 124, an ipsilateral graft leg 126 and a contralateral graft leg 128. The inflatable graft 114 may further include a fill port 116 in fluid communication with an inflation tube 118 of the endovascular delivery system 100 for providing an inflation medium (not shown). The distal portion of the endovascular delivery system 100 may include a nosecone 120 which provides an atraumatic distal portion of the endovascular delivery system 100. The guidewire 102 is slidably disposed within a guidewire lumen 122 of the endovascular delivery system 100.
As depicted in
As depicted in
Once the proximal stent 108 has been partially or fully deployed, the proximal inflatable cuff 134 may then be filled through the inflation port 116 with inflation material injected through an inflation tube 118 of the endovascular delivery system 100 which may serve to seal an outside surface of the inflatable cuff 134 to the inside surface of the vessel 10. The remaining network of inflatable channels 136 may also be filled with pressurized inflation material at the same time which provides a more rigid frame like structure to the inflatable graft 114. For some embodiments, the inflation material may be a biocompatible, curable or hardenable material that may cured or hardened once the network of inflatable channels 136 are filled to a desired level of material or pressure within the network or after passage of a predetermined period of time. Some embodiments may also employ radiopaque inflation material to facilitate monitoring of the fill process and subsequent engagement of graft extensions (not shown). The material may be cured by any of the suitable methods discussed herein including time lapse, heat application, application of electromagnetic energy, ultrasonic energy application, chemical adding or mixing or the like. Some embodiments for the inflation material that may be used to provide outward pressure or a rigid structure from within the inflatable cuff 134 or network of inflatable channels 136 may include inflation materials formed from glycidyl ether and amine materials. Some inflation material embodiments may include an in situ formed hydrogel polymer having a first amount of diamine and a second amount of polyglycidyl ether wherein each of the amounts are present in a mammal or in a medical device, such as an inflatable graft, located in a mammal in an amount to produce an in situ formed hydrogel polymer that is biocompatible and has a cure time after mixing of about 10 seconds to about 30 minutes and wherein the volume of said hydrogel polymer swells less than 30 percent after curing and hydration. Some embodiments of the inflation material may include radiopaque material such as sodium iodide, potassium iodide, barium sulfate, Visipaque 320, Hypaque, Omnipaque 350, Hexabrix and the like. For some inflation material embodiments, the polyglycidyl ether may be selected from trimethylolpropane triglycidyl ether, sorbitol polyglycidyl ether, polyglycerol polyglycidyl ether, pentaerythritol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, trimethylolpropane polyglycidyl ether, polyethylene glycol diglycidyl ether, resorcinol diglycidyl ether, glycidyl ester ether of p-hydroxy benzoic acid, neopentyl glycol diglycidyl ether, 1,6-hexanediol diglycidyl ether, bisphenol A (PO)2 diglycidyl ether, hydroquinone diglycidyl ether, bisphenol S diglycidyl ether, terephthalic acid diglycidyl ester, and mixtures thereof. For some inflation material embodiments, the diamine may be selected from (poly)alkylene glycol having amino or alkylamino termini selected from the group consisting of polyethylene glycol (400) diamine, di-(3-aminopropyl) diethylene glycol, polyoxypropylenediamine, polyetherdiamine, polyoxyethylenediamine, triethyleneglycol diamine and mixtures thereof. For some embodiments, the diamine may be hydrophilic and the polyglycidyl ether may be hydrophilic prior to curing. For some embodiments, the diamine may be hydrophilic and the polyglycidyl ether is hydrophobic prior to curing. For some embodiments, the diamine may be hydrophobic and the polyglycidyl ether may be hydrophilic prior to curing.
The network of inflatable channels 136 may be partially or fully inflated by injection of a suitable inflation material into the main fill port 116 to provide rigidity to the network of inflatable channels 136 and the graft 114. In addition, a seal is produced between the inflatable cuff 134 and the inside surface of the abdominal aorta 10. Although it is desirable to partially or fully inflate the network of inflatable channels 136 of the graft 114 at this stage of the deployment process, such inflation step optionally may be accomplished at a later stage if necessary.
Once the graft 114 is deployed and the inflatable channels 136 thereof have been filled and expanded, another delivery catheter (not shown) may be used to deploy a contralateral graft extension 138, as depicted in
For some deployment embodiments, the patient's hypogastric arteries may be used to serve as a positioning reference point to ensure that the hypogastric arteries are not blocked by the deployment. Upon such a deployment, the distal end of a graft extension 138 or 140 may be deployed anywhere within a length of the ipsilateral leg 126 or contralateral leg 128 of the graft 114. Also, although only one graft extension 140, 138 is shown deployed on the ipsilateral side and contralateral side of the graft assembly 114, additional graft extensions 140, 138 may be deployed within the already deployed graft extensions 140, 138 in order to achieve a desired length extension of the ipsilateral leg 126 or contralateral leg 128. For some embodiments, about 1 to about 5 graft extensions 138, 140 may be deployed on either the ipsilateral or contralateral sides of the graft assembly 114. Successive graft extensions 138, 140 may be deployed within each other so as to longitudinally overlap fluid flow lumens of successive graft extensions.
Graft extensions 138, 140, which may be interchangeable for some embodiments, or any other suitable extension devices or portions of the main graft section 124 may include a variety of suitable configurations. For some embodiments, graft extensions 138, 140 may include a polytetrafluoroethylene (PTFE) graft 142 with helical nitinol stent 144.
Further details of the endovascular prosthesis 106 and/or graft extensions 138, 140 may be found in commonly owned U.S. Pat. Nos. 6,395,019; 7,081,129; 7,147,660; 7,147,661; 7,150,758; 7,615,071; 7,766,954 and 8,167,927 and commonly owned U.S. Published Application No. 2009/0099649, the contents of all of which are incorporated herein by reference in their entirety. Details for the manufacture of the endovascular prosthesis 106 may be found in commonly owned U.S. Pat. Nos. 6,776,604; 7,090,693; 7,125,464; 7,147,455; 7,678,217 and 7,682,475, the contents of all of which are incorporated herein by reference in their entirety. Useful inflation materials for the inflatable graft 114 may be found in may be found in commonly owned U.S. Published Application No. 2005/0158272 and 2006/0222596, the contents of all of which are incorporated herein by reference in their entirety. Additional details of an endovascular delivery system having an improved radiopaque marker system for accurate prosthesis delivery may be found in commonly owned U.S. Provisional Application No. 61/660,413, entitled “Endovascular Delivery System With An Improved Radiopaque Marker Scheme”, filed Jun. 15, 2012, the contents of which are incorporated the herein by reference in their entirety.
Useful graft materials for the endovascular prosthesis 106 include, but are not limited, polyethylene; polypropylene; polyvinyl chloride; polytetrafluoroethylene (PTFE); fluorinated ethylene propylene; fluorinated ethylene propylene; polyvinyl acetate; polystyrene; poly(ethylene terephthalate); naphthalene dicarboxylate derivatives, such as polyethylene naphthalate, polybutylene naphthalate, polytrimethylene naphthalate and trimethylenediol naphthalate; polyurethane, polyurea; silicone rubbers; polyamides; polyimides; polycarbonates; polyaldehydes; polyether ether ketone; natural rubbers; polyester copolymers; silicone; styrene-butadiene copolymers; polyethers; such as fully or partially halogenated polyethers; and copolymers and combinations thereof. In some embodiments, the graft materials are non-textile graft materials, e.g., materials that are not woven, knitted, filament-spun, etc. that may be used with textile grafts. Such useful graft material may be extruded materials. Particularly useful materials include porous polytetrafluoroethylene without discernable node and fibril microstructure and (wet) stretched PTFE layer having low or substantially no fluid permeability that includes a closed cell microstructure having high density regions whose grain boundaries are directly interconnected to grain boundaries of adjacent high density regions and having substantially no node and fibril microstructure, and porous PTFE having no or substantially no fluid permeability. Such PTFE layers may lack distinct, parallel fibrils that interconnect adjacent nodes of ePTFE, typically have no discernable node and fibril microstructure when viewed at a magnification of up to 20,000. A porous PTFE layer having no or substantially no fluid permeability may have a Gurley Number of greater than about 12 hours, or up to a Gurley Number that is essentially infinite, or too high to measure, indicating no measurable fluid permeability. Some PTFE layers having substantially no fluid permeability may have a Gurley Number at 100 cc of air of greater than about 106 seconds. The Gurley Number is determined by measuring the time necessary for a given volume of air, typically, 25 cc, 100 cc or 300 cc, to flow through a standard 1 square inch of material or film under a standard pressure, such as 12.4 cm column of water. Such testing maybe carried out with a Gurley Densometer, made by Gurley Precision Instruments, Troy, N.Y. Details of such useful PTFE materials and methods for manufacture of the same may be found in commonly owned U.S. Patent Application Publication No. 2006/0233991, the contents of which are incorporated herein by reference in their entirety.
The flush port 154 for the outer sheath 104 may be used to flush the outer sheath 104 during delivery stages. The outer sheath 104 may have a radiopaque marker band to aid the practitioner in properly navigating the delivery system 100 to the desired bodily site. The outer sheath 104 is retractable by movement of the retraction knob or handle 152 for the outer sheath 104 by a practitioner towards the proximal handle assembly 170 of the delivery system 100. The inner tubular member or hypotube 150 is disposed from the inner tubular member or hypotube 150 toward a proximal portion of the delivery system 100. The inflation material or polymer fill connector port 158 and the inflation material or polymer fill cap 160 are useful for providing inflation material (e.g., polymeric fill material) to inflate proximal inflatable cuffs 134 and the network of inflatable channels 136 of the inflatable graft 114. The guidewire flush port 162 and the guidewire flush port cap 164 are useful for flushing the guidewire port 166 during delivery stages of the delivery system 100. The nested stent release knobs 168 contains a series of nested knobs (not shown) that that are used to engage release mechanisms for delivery of the endovascular prosthesis 106. Further details, including but not limited to methods, catheters and systems, for deployment of endovascular prostheses are disclosed in commonly owned U.S. Pat. Nos. 6,761,733 and 6,733,521 and commonly owned U.S. Patent Application Publication Nos. 2006/0009833 and 2009/0099649, all of which are incorporated by reference herein in their entirety.
In some embodiments, the tether 192 can withstand aggressive cannulation without disconnecting from the contralateral leg 128. For example, the tether 192 may have a tensile strength greater than 0.5 pounds-force per square inch (psi), which is an approximate maximum force which may be applied clinically. The tether 192 may have a tensile strength of about 2.0 psi. Such a tensile strength is non-limiting. Use of the contralateral tether 192 also allows filling of the inflatable graft 114 without impingement of the fill tube 116 or the network of channels 136. In the case of narrow distal aortic necks or in acute aortoiliac angles, a “ballerina” type crossover configuration (also referred to as a “barber pole: configuration) of the ipsilateral and contralateral graft legs may be used by a practitioner. In such a “ballerina” type crossover configuration the two iliac graft limbs may cross each other one or more times distal to the aortic body but before entering the iliac arteries of a patient treated with a bifurcated graft. Such a “ballerina” type crossover configuration may be achieved even with the use of the tether 192 with the inflatable graft 114 of the present invention. Moreover, use of the tether 192 prevents undesirably leg 126, 128 flipping during positioning of the inflatable graft 114.
The tether 192 width may be from about 2 to 5 mm, and its length may be from about 5 to 20 mm. These dimensions are non-limiting dimensions, and other suitable dimensions may be used. For example, in some embodiments (not shown), the contralateral tether 192 may have an ipsilateral end 198 that is not configured for engagement with a release wire 190 but rather is configured to run through the inner tubular member 150 and terminate at the proximal handle assembly 170 of the delivery system and releasably secured to a component thereof, such as an additional knob on handle assembly 170. A longer contralateral tether 192 of such a configuration may be manipulated by the physician-user in the same manner to mitigate or prevent undesirable movement or rotation of one or both legs 126, 128 during positioning of the inflatable graft 114 as described herein. This may provide beneficial positioning control or manipulation of the legs 126, 128, as opposed to must mitigating or preventing undesirable movement. Such a longer tether 192 would not necessary have to come all the way out of the handle 170, but alternatively could be engaged by a control wire or other control mechanism terminating at or near the handle 170.
The present invention, however, is not limited to the use of the tether 192 to restrain the contralateral leg 128 during deployment, and other suitably arrangements may be used. For example, as depicted in
The present invention, however, is not limited to the use of the above-described tether 192, the above-described release wire 190 and/or the above-described a loop 202 to restrain the contralateral leg 128 during deployment, and other suitably arrangements may be used. For example, as depicted in
As depicted in
The web 210 may be shaped, configured or constructed to allow more leg independent mobility at the distal portions of the legs 126, 128 as compared to proximal leg portions near the bifurcation portion of the graft or prosthesis 106. For example, the web 210 may have a curved and/or indented distal edge(s) or portion(s) near the distal portions of the legs 126, 128, where such curved and/or indented distal web edge(s) or portion(s) allows or permits the legs 126, 128 more relative independent movement as compared to a regular-shaped or triangular-shaped web 210 as depicted in
The following embodiments or aspects of the invention may be combined in any fashion and combination and be within the scope of the present invention, as follows:
An endovascular delivery system, comprising:
The endovascular delivery system of embodiment 1, wherein, when said release wire engages said tether, the open end of the contralateral leg is proximally disposed and restrained towards the open end of the ipsilateral leg.
The endovascular delivery system of embodiment 2, wherein the contralateral leg is restricted from significant longitudinal movement so as to prevent bunching up of the contralateral leg.
The endovascular delivery system of embodiment 2, wherein the contralateral leg is restricted from significant rotational movement so as to prevent misalignment within a bodily lumen.
The endovascular delivery system of embodiment 1, wherein said elongate guidewire is extendable through the ipsilateral leg and through the main tubular body.
The endovascular delivery system of embodiment 1, further comprising:
The endovascular delivery system of embodiment 1, wherein the prosthesis comprises non-textile polymeric material.
The endovascular delivery system of embodiment 1, wherein the non-textile polymeric material of the prosthesis comprises extruded polytetrafluoroethylene.
The endovascular delivery system of embodiment 8, wherein said extruded polytetrafluoroethylene is non-porous polytetrafluoroethylene.
The endovascular delivery system of embodiment 1, wherein the prosthesis further comprises a metallic expandable member securably disposed at or near the open end of the main tubular body of said prosthesis.
A method for delivering a bifurcated prosthesis, comprising:
The method of embodiment 11, wherein, when said release wire engages said tether, the open end of the contralateral leg is proximally disposed and restrained towards the open end of the ipsilateral leg.
The method of embodiment 12, wherein the contralateral leg is restricted from significant longitudinal movement so as to prevent bunching up of the contralateral leg.
The method of embodiment 12, wherein the contralateral leg is restricted from significant rotational movement so as to prevent misalignment within a bodily lumen.
An endovascular prosthesis, comprising:
The endovascular prosthesis of embodiment 15, wherein the contralateral leg is restricted from significant rotational movement so as to prevent misalignment within a bodily lumen.
The endovascular prosthesis of embodiment 15, wherein the web is releasably secured to the contralateral leg and the ipsilateral leg.
While various embodiments of the present invention are specifically illustrated and/or described herein, it will be appreciated that modifications and variations of the present invention may be effected by those skilled in the art without departing from the spirit and intended scope of the invention. Further, any of the embodiments or aspects of the invention as described in the claims or in the specification may be used with one and another without limitation.
This application is a continuation of U.S. application Ser. No. 16/267,264, filed Feb. 4, 2019, which is a continuation of U.S. application Ser. No. 15/299,542, filed Oct. 21, 2016, now U.S. Pat. No. 10,195,060, granted Feb. 5, 2019, which is a continuation of U.S. application Ser. No. 14/823,076, filed Aug. 11, 2015, now U.S. Pat. No. 9,585,774, granted Mar. 7, 2017, which is a continuation of U.S. application Ser. No. 13/803,067, filed Mar. 14, 2013, now U.S. Pat. No. 9,132,025, granted Sep. 15, 2015, which claims the benefit of U.S. Provisional Application No. 61/660,105, filed Jun. 15, 2012, the contents of all of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
5197973 | Herweck et al. | Mar 1993 | A |
5197976 | Herweck et al. | Mar 1993 | A |
6210435 | Piplani et al. | Apr 2001 | B1 |
6214038 | Piplani et al. | Apr 2001 | B1 |
6235050 | Quiachon et al. | May 2001 | B1 |
6241759 | Piplani et al. | Jun 2001 | B1 |
6248118 | Tanner et al. | Jun 2001 | B1 |
6270516 | Tanner et al. | Aug 2001 | B1 |
6305164 | Kujawski | Oct 2001 | B1 |
6322587 | Quiachon et al. | Nov 2001 | B1 |
6355061 | Quiachon et al. | Mar 2002 | B1 |
6371919 | Tanner et al. | Apr 2002 | B1 |
6371982 | Berg | Apr 2002 | B2 |
6395019 | Chobotov | May 2002 | B2 |
6395022 | Piplani et al. | May 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6409757 | Trout, III et al. | Jun 2002 | B1 |
6416542 | Marcade et al. | Jul 2002 | B1 |
6464721 | Marcade et al. | Oct 2002 | B1 |
6520974 | Tanner et al. | Feb 2003 | B2 |
6540778 | Quiachon et al. | Apr 2003 | B1 |
6576009 | Ryan | Jun 2003 | B2 |
6592615 | Marcade et al. | Jul 2003 | B1 |
6635066 | Tanner et al. | Oct 2003 | B2 |
6660033 | Marcade et al. | Dec 2003 | B1 |
6663666 | Quiachon et al. | Dec 2003 | B1 |
6669718 | Besselink | Dec 2003 | B2 |
6676694 | Weiss | Jan 2004 | B1 |
6682537 | Ouriel et al. | Jan 2004 | B2 |
6682557 | Quiachon et al. | Jan 2004 | B1 |
6695875 | Stelter et al. | Feb 2004 | B2 |
6761733 | Chobotov et al. | Jul 2004 | B2 |
6767361 | Quiachon et al. | Jul 2004 | B2 |
6776604 | Choboto et al. | Aug 2004 | B1 |
6802859 | Pazienza et al. | Oct 2004 | B1 |
6808534 | Escano | Oct 2004 | B1 |
6878164 | Kujawski et al. | Apr 2005 | B2 |
6964679 | Marcade et al. | Nov 2005 | B1 |
6984244 | Perez et al. | Jan 2006 | B2 |
7029496 | Rakos et al. | Apr 2006 | B2 |
7081129 | Chobotov | Jul 2006 | B2 |
7090693 | Chobotov et al. | Aug 2006 | B1 |
7118594 | Quiachon et al. | Oct 2006 | B2 |
7125464 | Chobotov et al. | Oct 2006 | B2 |
7147455 | Chobotov et al. | Dec 2006 | B2 |
7147660 | Chobotov et al. | Dec 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7150758 | Kari et al. | Dec 2006 | B2 |
7195639 | Quiachon et al. | Mar 2007 | B2 |
7235083 | Perez et al. | Jun 2007 | B1 |
7235095 | Haverkost et al. | Jun 2007 | B2 |
7294147 | Hartley | Nov 2007 | B2 |
7435253 | Hartley et al. | Oct 2008 | B1 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7520894 | Pavcnik et al. | Apr 2009 | B2 |
7527645 | Perez et al. | May 2009 | B2 |
7597710 | Obermiller | Oct 2009 | B2 |
7604661 | Pavcnik et al. | Oct 2009 | B2 |
7615071 | Chobotov | Nov 2009 | B2 |
7628803 | Pavcnik et al. | Dec 2009 | B2 |
7678217 | Chobotov et al. | Mar 2010 | B2 |
7682475 | Chobotov et al. | Mar 2010 | B2 |
7766954 | Chobotov et al. | Aug 2010 | B2 |
7803574 | Desai et al. | Sep 2010 | B2 |
7918882 | Pavcnik et al. | Apr 2011 | B2 |
7972616 | Dubrow et al. | Jul 2011 | B2 |
8118862 | Saeed | Feb 2012 | B2 |
8128680 | Arnault et al. | Mar 2012 | B2 |
8128686 | Paul, Jr. et al. | Mar 2012 | B2 |
8167927 | Chobotov et al. | May 2012 | B2 |
20010016748 | Tanner et al. | Aug 2001 | A1 |
20010037142 | Stelter et al. | Nov 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20020007193 | Tanner et al. | Jan 2002 | A1 |
20020013620 | Kujawski | Jan 2002 | A1 |
20020026214 | Tanner et al. | Feb 2002 | A1 |
20020077692 | Besselink | Jun 2002 | A1 |
20020151953 | Chobotov et al. | Oct 2002 | A1 |
20030004560 | Chobotov et al. | Jan 2003 | A1 |
20030088306 | Rakos et al. | May 2003 | A1 |
20030120263 | Ouriel et al. | Jun 2003 | A1 |
20030158597 | Quiachon et al. | Aug 2003 | A1 |
20030163188 | Haverkost et al. | Aug 2003 | A1 |
20030167087 | Piplani et al. | Sep 2003 | A1 |
20030176912 | Chuter et al. | Sep 2003 | A1 |
20040002714 | Weiss | Jan 2004 | A1 |
20040054401 | Kujawski et al. | Mar 2004 | A1 |
20040082990 | Hartley | Apr 2004 | A1 |
20040117004 | Osborne et al. | Jun 2004 | A1 |
20040138734 | Chobotov et al. | Jul 2004 | A1 |
20040153143 | Quiachon et al. | Aug 2004 | A1 |
20040186558 | Pavcnik et al. | Sep 2004 | A1 |
20040193252 | Perez et al. | Sep 2004 | A1 |
20040210301 | Obermiller | Oct 2004 | A1 |
20040213766 | Francois | Oct 2004 | A1 |
20040243221 | Fawzi et al. | Dec 2004 | A1 |
20050015141 | Quiachon et al. | Jan 2005 | A1 |
20050038498 | Dubrow et al. | Feb 2005 | A1 |
20050043785 | Tanner et al. | Feb 2005 | A1 |
20050084514 | Shebuski et al. | Apr 2005 | A1 |
20050143807 | Pavcnik et al. | Jun 2005 | A1 |
20050158272 | Whirley et al. | Jul 2005 | A1 |
20050177224 | Fogarty et al. | Aug 2005 | A1 |
20050187613 | Bolduc et al. | Aug 2005 | A1 |
20050221072 | Dubrow et al. | Oct 2005 | A1 |
20050228484 | Stephens et al. | Oct 2005 | A1 |
20060009833 | Chobotov et al. | Jan 2006 | A1 |
20060015176 | White et al. | Jan 2006 | A1 |
20060020326 | Bolduc et al. | Jan 2006 | A9 |
20060036314 | Perez et al. | Feb 2006 | A1 |
20060111770 | Pavcnik et al. | May 2006 | A1 |
20060142846 | Pavcnik et al. | Jun 2006 | A1 |
20060155358 | Laduca et al. | Jul 2006 | A1 |
20060155363 | Laduca et al. | Jul 2006 | A1 |
20060161245 | Rakos et al. | Jul 2006 | A1 |
20060204738 | Dubrow et al. | Sep 2006 | A1 |
20060222596 | Askari et al. | Oct 2006 | A1 |
20060233991 | Humphrey et al. | Oct 2006 | A1 |
20060286063 | Shebuski et al. | Dec 2006 | A1 |
20070010875 | Trout et al. | Jan 2007 | A1 |
20070050015 | O'Brien et al. | Mar 2007 | A1 |
20070150051 | Arnault De La Menardiere et al. | Jun 2007 | A1 |
20070156228 | Majercak et al. | Jul 2007 | A1 |
20070167955 | Arnault De La Menardiere et al. | Jul 2007 | A1 |
20070225797 | Krivoruhko | Sep 2007 | A1 |
20070282247 | Desai et al. | Dec 2007 | A1 |
20070299498 | Perez et al. | Dec 2007 | A1 |
20080039362 | Shebuski et al. | Feb 2008 | A1 |
20080039926 | Majercak et al. | Feb 2008 | A1 |
20080097586 | Pavcnik et al. | Apr 2008 | A1 |
20080103587 | Henderson | May 2008 | A1 |
20080183274 | Laduca et al. | Jul 2008 | A1 |
20080208309 | Saeed | Aug 2008 | A1 |
20080221668 | Pinchuk et al. | Sep 2008 | A1 |
20080255656 | Saeed | Oct 2008 | A1 |
20080275542 | Laduca et al. | Nov 2008 | A1 |
20080288045 | Saeed | Nov 2008 | A1 |
20090005847 | Adams | Jan 2009 | A1 |
20090043373 | Arnault De La Menardiere et al. | Feb 2009 | A1 |
20090048662 | Pavcnik et al. | Feb 2009 | A1 |
20090099649 | Chobotov et al. | Apr 2009 | A1 |
20090125095 | Bui et al. | May 2009 | A1 |
20090132026 | Martin et al. | May 2009 | A1 |
20090138067 | Pinchuk et al. | May 2009 | A1 |
20090157169 | Pavcnik et al. | Jun 2009 | A1 |
20090162643 | Dubrow et al. | Jun 2009 | A1 |
20090182405 | Arnault De La Menardiere et al. | Jul 2009 | A1 |
20090202621 | Maldonado et al. | Aug 2009 | A1 |
20090222077 | Caldarise et al. | Sep 2009 | A1 |
20090259296 | McIff et al. | Oct 2009 | A1 |
20090264991 | Paul, Jr. et al. | Oct 2009 | A1 |
20090270967 | Fleming, III | Oct 2009 | A1 |
20090299455 | Sutermeister et al. | Dec 2009 | A1 |
20090299462 | Fawzi et al. | Dec 2009 | A1 |
20090301182 | Nikanorov | Dec 2009 | A1 |
20090319029 | Evans et al. | Dec 2009 | A1 |
20100057191 | Pavcnik et al. | Mar 2010 | A1 |
20100161028 | Chuter et al. | Jun 2010 | A1 |
20100179583 | Carpenter et al. | Jul 2010 | A1 |
20100179584 | Carpenter et al. | Jul 2010 | A1 |
20100179585 | Carpenter et al. | Jul 2010 | A1 |
20100179647 | Carpenter et al. | Jul 2010 | A1 |
20100298923 | Sutermeister et al. | Nov 2010 | A1 |
20100324589 | Carpenter et al. | Dec 2010 | A1 |
20100324647 | Rincon | Dec 2010 | A1 |
20110201984 | Dubrow et al. | Aug 2011 | A1 |
20120012569 | Severino | Jan 2012 | A1 |
20120022636 | Chobotov | Jan 2012 | A1 |
20120029608 | Chobotov | Feb 2012 | A1 |
Number | Date | Country |
---|---|---|
2 111 828 | Oct 2009 | EP |
2111828 | Oct 2009 | EP |
WO 0069367 | Nov 2000 | WO |
WO-0069367 | Nov 2000 | WO |
WO 2013151924 | Oct 2013 | WO |
WO-2013151924 | Oct 2013 | WO |
Entry |
---|
International Search Report and Written Opinion dated Nov. 6, 2013 for corresponding PCT application. |
European Office Action dated Nov. 22, 2017, from application No. 13733115.3. |
Extended European Search Report dated May 2, 2019, from application No. 18209876.4. |
Non-Final Office Action dated Jun. 9, 2020, from U.S. Appl. No. 16/267,264. |
Notice of Allowance dated Jan. 14, 2021, from U.S. Appl. No. 16/267,264. |
U.S. Final Office Action dated Apr. 26, 2018, from U.S. Appl. No. 15/299,542. |
U.S. Final Office Action dated Jun. 20, 2017, from U.S. Appl. No. 15/299,542. |
U.S. Non-final Office Action dated Dec. 23, 2016, from U.S. Appl. No. 15/299,542. |
U.S. Non-final Office Action dated Nov. 15, 2017, from U.S. Appl. No. 15/299,542. |
U.S. Notice of Allowance dated Sep. 21, 2018, from U.S. Appl. No. 15/299,542. |
Number | Date | Country | |
---|---|---|---|
20210251782 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
61660105 | Jun 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16267264 | Feb 2019 | US |
Child | 17313509 | US | |
Parent | 15299542 | Oct 2016 | US |
Child | 16267264 | US | |
Parent | 14823076 | Aug 2015 | US |
Child | 15299542 | US | |
Parent | 13803067 | Mar 2013 | US |
Child | 14823076 | US |